Immunotherapy and radiation therapy sequencing: State of the data on timing, efficacy, and safety

Cancer. 2021 May 15;127(10):1553-1567. doi: 10.1002/cncr.33424. Epub 2021 Feb 23.

Abstract

Radiation therapy exerts a tumoricidal local effect as well as both local and systemic immunomodulation. Immune checkpoint blockade has become a widely used treatment modality across cancer types with a rapidly growing list of agents and US Food and Drug Administration-approved indications. Moreover, there may be synergy between radiation therapy and immune checkpoint blockade. Various strategies have been used, but the optimal sequencing of these therapies is unclear. In this review, the authors discuss the major mechanisms of available immune checkpoint inhibitors and explore the available preclinical and clinical evidence regarding treatment sequencing. They also review safety considerations and conclude with possible future directions.

Keywords: cancer therapy sequencing; immune checkpoint blockade; immunotherapy; radiation therapy; radiosensitization.

Publication types

  • Review

MeSH terms

  • Combined Modality Therapy / adverse effects
  • Humans
  • Immune Checkpoint Inhibitors / adverse effects
  • Immunotherapy* / adverse effects
  • Neoplasms* / radiotherapy
  • Neoplasms* / therapy
  • Time Factors
  • Treatment Outcome

Substances

  • Immune Checkpoint Inhibitors